Review: weight-reducing agents improve glycaemic control and reduce progression to diabetes
Dr S Czernichow, Unite de Recherche en Nutrition Humaine, Bobigny, France; email@example.com
How do weight-reducing agents affect glycaemic parameters and risk of type 2 diabetes in predisposed individuals?
Included studies were randomised, double-blind, placebo controlled trials (RCTs) that evaluated the effects of weight-reducing agents (eg, orlistat, sibutramine, and rimonabant) on fasting glucose or glycated haemoglobin (HbA1c) concentrations and had a duration of ⩾1 year. Studies of mixed populations were excluded. Outcomes included weight loss, fasting glucose and HbA1c concentrations, and diabetes.
Medline was searched from …